Longeveron Q1 Revenue $398,000, Exceeds Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Reports Q1 revenue $398,000, consensus $323,000. "Earlier this year, we initiated a strategic repositioning of Longeveron designed to maximize shareholder value while maintaining disciplined capital allocation," said Stephen H. Willard, Chief Executive Officer of Longeveron. "We have transitioned toward a more capital-efficient, asset-light operating model, with an increased focus on securing strategic licensing partnerships for our stem cell therapy laromestrocel in four development programs. Longeveron is approaching a series of potentially transformative milestones across these programs that have the potential to redefine the trajectory of our business, with the first catalyst, top line results from our Phase 2b clinical trial in HLHS, anticipated in August of this year."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LGVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LGVN
Wall Street analysts forecast LGVN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.811
Low
3.00
Averages
3.50
High
4.00
Current: 0.811
Low
3.00
Averages
3.50
High
4.00
About LGVN
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Longeveron Q1 2026 Earnings Call Insights
- Financial Performance: In Q1 2026, Longeveron reported a net loss of $4.7 million, an improvement from $5 million in Q1 2025, indicating efforts in cost control but still facing financial pressures.
- Clinical Trial Progress: The company anticipates top-line results from the ELPIS II trial in August 2026, although unfavorable FDA feedback on the primary endpoint highlights uncertainties in clinical development.
- Strategic Shift: Longeveron is transitioning to a more capital-efficient asset-light operating model, focusing on securing strategic licensing partnerships to advance its stem cell product development, aiming to enhance market competitiveness.
- Regulatory Challenges: The FDA has stated that the right ventricular ejection fraction is no longer considered an appropriate endpoint for demonstrating efficacy in the ELPIS II trial, which may impact future biological license application pathways, with management expressing cautious optimism about the situation.
See More
Longeveron Advances Phase 2b Trial for HLHS
- Trial Progress: Longeveron's ELPIS II clinical trial has fully enrolled 40 pediatric patients to evaluate laromestrocel as an adjunct therapy for HLHS, with top-line results expected in August 2026, demonstrating the company's ongoing commitment to rare disease treatment.
- Safety Assessment: The independent Data Monitoring Committee (DMC) completed its final safety assessment of the trial, identifying no new safety concerns and approving the study to continue as planned, indicating the potential safety and efficacy of the therapy.
- FDA Designations: Laromestrocel has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, highlighting its significance in HLHS treatment and potentially establishing a strong market opportunity for the company.
- Market Need: HLHS affects approximately 1,000 infants annually in the U.S., and despite complex existing treatments, long-term mortality and morbidity remain substantial; the development of laromestrocel aims to address this unmet medical need, presenting significant market potential.
See More
Longeveron Advances FDA Discussions on ELPIS II Trial
- FDA Meeting Outcome: Longeveron held a constructive Type C meeting with the FDA, which acknowledged HLHS as a rare disease with high unmet needs but indicated that the primary endpoint, right ventricular ejection fraction (RVEF), is insufficient to demonstrate efficacy, potentially impacting the company's future clinical trial strategies.
- Trial Adjustment Limitations: While Longeveron agreed with the FDA's concerns, changes to the primary endpoint cannot be made mid-trial due to NIH-mandated interim analysis, meaning ELPIS II is no longer considered pivotal, which may delay its market approval process.
- Future Plans: Longeveron intends to submit a Sponsor Statistical Analysis Plan (SAP) with a composite primary endpoint and secondary endpoints for FDA review, aiming to integrate more evidence to support a Biologics License Application (BLA), demonstrating the company's confidence in trial results.
- Clinical Trial Context: Topline results from the 40-patient ELPIS II trial are anticipated in August 2026, capturing objective measures such as mortality, transplant-free survival, and major adverse cardiac events to support efficacy assessment, underscoring the importance of new therapies in HLHS treatment.
See More
FDA Raises Concerns Over Longeveron's Cell Therapy Trial Design
- FDA Trial Design Concerns: The FDA explicitly stated that Longeveron's laromestrocel trial's current primary endpoint is “not appropriate to demonstrate efficacy,” resulting in the study no longer being considered “pivotal,” which could hinder future approval processes.
- Clinical Trial Data Expectations: Despite the FDA's reservations about the trial design, Longeveron still anticipates top-line data from the 40-patient randomized controlled study in August 2026, which, if positive, could support future application filings.
- Investor Sentiment Shift: Following the FDA meeting, retail sentiment around LGVN stock shifted from 'bearish' to 'neutral' within 24 hours, although the stock has fallen 43% over the past year, indicating cautious optimism among investors regarding future developments.
- Revised Plan Submission: Longeveron plans to submit a revised plan featuring a composite primary endpoint and secondary endpoints, and while the FDA indicated it could not agree to a new primary endpoint during the ongoing trial, the company remains optimistic that the final dataset will support an application.
See More
Longeveron Discusses ELPIS II with FDA
- FDA Meeting Outcomes: Longeveron held a constructive meeting with the FDA in March to discuss the development of laromestrocel, with the FDA acknowledging HLHS as a rare disease with significant unmet medical needs, although expressing concerns about the primary endpoint's efficacy.
- Clinical Trial Progress: Top-line results from the ELPIS II clinical trial are expected in August 2026, with the FDA indicating that a new primary endpoint cannot be agreed upon while the trial is ongoing, affecting the trial's pivotal designation.
- Data Collection Strategy: The company is capturing objective measures such as all-cause mortality and cardiac transplant-free survival in ELPIS II to support efficacy determination, planning to submit a statistical analysis plan with a composite primary endpoint to the FDA.
- Future Outlook: Despite challenges, Longeveron remains optimistic about the trial results, believing that the data will support its Biologics License Application (BLA) and potentially qualify for a Priority Review Voucher from the FDA.
See More
Avaí Bio Advances Anti-Aging Therapeutics Development
- Market Growth Potential: The global anti-aging market surpassed $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science doubling to $8.49 billion last year, indicating strong growth potential in this sector.
- FDA Drug Approvals: The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025, including the first drug class termed 'longevity therapeutics', highlighting a rapid transformation in the biopharmaceutical industry that is driving market demand.
- Avaí Bio's Strategic Shift: Avaí Bio completed its rebranding in February 2026, focusing on developing cellular therapies for diabetes and age-related diseases, leveraging genetically engineered cells and protective encapsulation technology to accelerate progress towards functional cures.
- Aging Population Drives Demand: Adults aged 60 and older represent 17% of the U.S. population but account for 37% of healthcare spending, with the global 60+ population expected to reach 1.4 billion by 2030, underscoring the urgent need for anti-aging treatments.
See More
Longeveron Q1 2026 Earnings Call Insights
- Financial Performance: In Q1 2026, Longeveron reported a net loss of $4.7 million, an improvement from $5 million in Q1 2025, indicating efforts in cost control but still facing financial pressures.
- Clinical Trial Progress: The company anticipates top-line results from the ELPIS II trial in August 2026, although unfavorable FDA feedback on the primary endpoint highlights uncertainties in clinical development.
- Strategic Shift: Longeveron is transitioning to a more capital-efficient asset-light operating model, focusing on securing strategic licensing partnerships to advance its stem cell product development, aiming to enhance market competitiveness.
- Regulatory Challenges: The FDA has stated that the right ventricular ejection fraction is no longer considered an appropriate endpoint for demonstrating efficacy in the ELPIS II trial, which may impact future biological license application pathways, with management expressing cautious optimism about the situation.
See More
Longeveron Advances Phase 2b Trial for HLHS
- Trial Progress: Longeveron's ELPIS II clinical trial has fully enrolled 40 pediatric patients to evaluate laromestrocel as an adjunct therapy for HLHS, with top-line results expected in August 2026, demonstrating the company's ongoing commitment to rare disease treatment.
- Safety Assessment: The independent Data Monitoring Committee (DMC) completed its final safety assessment of the trial, identifying no new safety concerns and approving the study to continue as planned, indicating the potential safety and efficacy of the therapy.
- FDA Designations: Laromestrocel has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA, highlighting its significance in HLHS treatment and potentially establishing a strong market opportunity for the company.
- Market Need: HLHS affects approximately 1,000 infants annually in the U.S., and despite complex existing treatments, long-term mortality and morbidity remain substantial; the development of laromestrocel aims to address this unmet medical need, presenting significant market potential.
See More
Longeveron Advances FDA Discussions on ELPIS II Trial
- FDA Meeting Outcome: Longeveron held a constructive Type C meeting with the FDA, which acknowledged HLHS as a rare disease with high unmet needs but indicated that the primary endpoint, right ventricular ejection fraction (RVEF), is insufficient to demonstrate efficacy, potentially impacting the company's future clinical trial strategies.
- Trial Adjustment Limitations: While Longeveron agreed with the FDA's concerns, changes to the primary endpoint cannot be made mid-trial due to NIH-mandated interim analysis, meaning ELPIS II is no longer considered pivotal, which may delay its market approval process.
- Future Plans: Longeveron intends to submit a Sponsor Statistical Analysis Plan (SAP) with a composite primary endpoint and secondary endpoints for FDA review, aiming to integrate more evidence to support a Biologics License Application (BLA), demonstrating the company's confidence in trial results.
- Clinical Trial Context: Topline results from the 40-patient ELPIS II trial are anticipated in August 2026, capturing objective measures such as mortality, transplant-free survival, and major adverse cardiac events to support efficacy assessment, underscoring the importance of new therapies in HLHS treatment.
See More
FDA Raises Concerns Over Longeveron's Cell Therapy Trial Design
- FDA Trial Design Concerns: The FDA explicitly stated that Longeveron's laromestrocel trial's current primary endpoint is “not appropriate to demonstrate efficacy,” resulting in the study no longer being considered “pivotal,” which could hinder future approval processes.
- Clinical Trial Data Expectations: Despite the FDA's reservations about the trial design, Longeveron still anticipates top-line data from the 40-patient randomized controlled study in August 2026, which, if positive, could support future application filings.
- Investor Sentiment Shift: Following the FDA meeting, retail sentiment around LGVN stock shifted from 'bearish' to 'neutral' within 24 hours, although the stock has fallen 43% over the past year, indicating cautious optimism among investors regarding future developments.
- Revised Plan Submission: Longeveron plans to submit a revised plan featuring a composite primary endpoint and secondary endpoints, and while the FDA indicated it could not agree to a new primary endpoint during the ongoing trial, the company remains optimistic that the final dataset will support an application.
See More
Longeveron Discusses ELPIS II with FDA
- FDA Meeting Outcomes: Longeveron held a constructive meeting with the FDA in March to discuss the development of laromestrocel, with the FDA acknowledging HLHS as a rare disease with significant unmet medical needs, although expressing concerns about the primary endpoint's efficacy.
- Clinical Trial Progress: Top-line results from the ELPIS II clinical trial are expected in August 2026, with the FDA indicating that a new primary endpoint cannot be agreed upon while the trial is ongoing, affecting the trial's pivotal designation.
- Data Collection Strategy: The company is capturing objective measures such as all-cause mortality and cardiac transplant-free survival in ELPIS II to support efficacy determination, planning to submit a statistical analysis plan with a composite primary endpoint to the FDA.
- Future Outlook: Despite challenges, Longeveron remains optimistic about the trial results, believing that the data will support its Biologics License Application (BLA) and potentially qualify for a Priority Review Voucher from the FDA.
See More
Avaí Bio Advances Anti-Aging Therapeutics Development
- Market Growth Potential: The global anti-aging market surpassed $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science doubling to $8.49 billion last year, indicating strong growth potential in this sector.
- FDA Drug Approvals: The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025, including the first drug class termed 'longevity therapeutics', highlighting a rapid transformation in the biopharmaceutical industry that is driving market demand.
- Avaí Bio's Strategic Shift: Avaí Bio completed its rebranding in February 2026, focusing on developing cellular therapies for diabetes and age-related diseases, leveraging genetically engineered cells and protective encapsulation technology to accelerate progress towards functional cures.
- Aging Population Drives Demand: Adults aged 60 and older represent 17% of the U.S. population but account for 37% of healthcare spending, with the global 60+ population expected to reach 1.4 billion by 2030, underscoring the urgent need for anti-aging treatments.
See More
